Interferon alpha-2b gene therapy - Aevi Genomic Medicine

Drug Profile

Interferon alpha-2b gene therapy - Aevi Genomic Medicine

Alternative Names: Infradure; Infradure Biopump

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Medgenics
  • Class Antivirals; Cytokine genes; IFNA2B gene therapies; Interferons
  • Mechanism of Action Gene transference; IFNA2B expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B; Hepatitis C; Hepatitis D

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Hepatitis D

Most Recent Events

  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 16 Apr 2014 Medgenics withdraws phaseI/II trial in Hepatitis C (recurrent) in Israel prior to enrolment (NCT01430000)
  • 01 Mar 2014 Medgenics terminates phase I/II trial in Hepatitis C in Israel (NCT01433133)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top